|
Published by: Visiongain
Published: Oct. 15, 2007
Table of Contents
- Chapter 1. Executive Summary
- Chapter 2. An Introduction to Alzheimer's Disease
- 2.1 Introduction
- 2.2 Symptoms and Differential Diagnosis
- 2.3 The Risk Factors for AD
- 2.4 Type of Protein as a Cause for AD?
- 2.4.1 Neuronal and Synaptic Loss of AD
- 2.4.2 Chromosomal Mutations of AD
- 2.4.3 Inflammation of AD
- 2.4.4 Using brain scans to detect Alzheimer's
- 2.5 The Demographics for AD
- 2.6 Financial Burden of AD
- Chapter 3. Pharmacotherapy for Alzheimer's Disease
- 3.1 Current AD Pharmaceutical Drug Therapies
- 3.2 Acetylcholinesterase Drugs - How do you Treat Mild to Moderate
- AD?
- 3.2.1 Pfizer/Eisai Aricept (Donepezil hyrdochloride) - The leading
- drug choice for AD
- 3.2.1 Aricept clinical data
- 3.2.1.1 Pre-clinical data
- 3.2.1.2 Aricept clinical data outcomes
- 3.2.1.3 Eisai and Pfizer Aricept post marketing research for AD
- 3.2.1.4 Eisai severe Alzheimer's disease trials
- 3.3 Novartis Excelon (Rivastigamine) - Popular Drug Therapy for AD
- 3.3.1 Excelon mild-to-moderately severe Alzheimer's disease clinical data
- 3.3.2 J&J/ Shire Razadyne (Galantamine) is a Mild-to-moderate Treatment for AD
- 3.3.3 J&J/ Shire Reminyl (Galantamine) clinical studies
- 3.3.4 Forest and Lundbeck (Namenda/Ebixa) The Drug Treatments for Moderate to Severe AD
- 3.3.4.1 Lundbeck Ebixa (Namenda) severe Alzheimer's disease clinical data
- 3.3.4.2 Lundbeck Ebixa (Namenda) mild-to-moderate Alzheimer's disease clinical data
- 3.3.5 Comparative efficacy of Clinical Approved AD drugs
- 3.3.6 Cognex (Tacrine)
- 3.3.7 Non steroidal anti-inflammatory drugs (NSAIDs)
- 3.4 Comorbid Conditions
- 3.5 Depression associated with Alzheimer's disease and its management
- Chapter 4. UK Alzheimer's Disease treatment guidelines
- 4.1 UK-National Institute for Clinical Excellence guidelines
- 4.2 NICE 2001 AD guideline
- 4.2.1 NICE reversal to 2001 AD guidance
- 4.2.2 Stakeholders' reaction to NICE 2001 AD guidelines reversal
- 4.2.3 NICE 2006 AD Guidance Review- Aricept, Razadyne, Exelon and Memantine
- 4.2.4 Judicial Review of NICE guideline 2007
- Chapter 5. Global AD market
- 5.1 Overview of Global AD market and Geographical analysis
- 5.2 US Alzheimer's disease market
- 5.3 US AD Market Drivers and Restraints
- 5.3.1 Market Drivers
- 5.3.2 Market Restraints
- 5.4 Japan Alzheimer's disease Market
- 5.5 Japan Market Drivers and Restraints
- 5.5.1 Market Drivers
- 5.5.2 Market Restraints
- 5.6 France Alzheimer's disease Market
- 5.7 France AD Market Drivers and Restraints
- 5.7.1 Market Drivers
- 5.7.2 Market Restraints
- 5.8 Germany Alzheimer's disease Market
- 5.9 Germany AD Market Drivers and Restraints
- 5.9.1 Market Drivers
- 5.9.2 Market Restraints
- 5.10 UK Alzheimer's disease Market
- 5.11 UK AD Market Drivers and Restraints
- 5.11.1 Market Drivers
- 5.11.2 Market Restraints
- 5.12 Italy's Alzheimer's disease Market
- 5.13 Italy AD Market Drivers and Restraints
- 5.13.1 Market Drivers
- 5.13.2 Market Restraints
- 5.14 Spain's Alzheimer's disease Market
- 5.15 Spain AD Market Drivers and Restraints
- 5.15.1 Market Drivers
- 5.15.2 Market Restraints
- Chapter 6. Key players in Alzheimer's Disease Pharmacotherapy
- 6.1 Eisai/Pfizer's Aricept
- 6.1.1 Eisai Aricept product expansion
- 6.1.2 Eisai R&D
- 6.2 Forest Laboratories Namenda /Lundbeck Ebixa product expansion
- 6.3 Shire Razadyne product expansion
- 6.4 Novartis Exelon product expansion
- 6.4.1 Novartis Exelon TransdermalPatch for AD
- 6.4.2 Potential Success of Exelon Transdermal Patch
- 6.4.3 Novartis' Exelon and Forest Namenda combinatorial study
- 6.5 Will there be generic competition?
- 6.6 Market growth indications
- Chapter 7. Alzheimer's disease R&D and pipeline
- 7.1 Unmet medical needs for Alzheimer's disease
- 7.2 Present clinical approaches to delivering AD therapies
- 7.2.1 Biomarkers a prospective diagnostic tool
- 7.3 Overview of pipeline products
- 7.3.1 Pipeline Drugs for AD
- 7.3.2 Neurochem's Alzhemed (anti-amyloid compound) illuminates strong therapeutic potential
- 7.3.3 Forest's Neramexane potential follow-on product for Namenda
- 7.3.4. Other compounds presently in the pipeline
- 7.3.4.1 PBT-1 (Coloquinol)
- 7.3.4.2 Phenserine
- 7.3.4.3 Allon Therapeutics'AL-108 and AL-208 to inhibit neuronal death
- 7.3.4.4 Martek's DHA reduces brain lesions in AD animal models
- 7.3.4.5 Phytopharm Cogane -an orally active neuroprotective compound
- 7.3.4.6 Nicotine Replacement Therapy as a Potential Treatment for AD
- 7.4 Emerging Therapies for Alzheimer's disease
- 7.4.1 Vitamin E (Antioxidants) for AD
- 7.4.2 Research has revealed that Vitamin E, Vitamin C and other
- health foods possess oxidative properties.
- 7.4.3 OTC Ginko Biloba May Slow AD Symptoms
- 7.4.4 Oestrogen HRT May Protect Against AD
- Chapter 8. Conclusions
- 8.1 Expansion of Global Population
- 8.2 Prevalence of Alzheimer's disease in the Major Markets
- 8.3 FDA Approved Alzheimer's disease Therapies and NICE's Cost-Effective Analysis
- 8.4 Alzheimer's disease Drug Sales across Major Markets 2006
- 8.5 Barriers to Generic entrants
- 8.6 Alzheimer's disease Revenue ($m) Forecast
- 8.7 Leading Companies with Products in late-stage Alzheimer's disease Pipeline
- List of Tables
- Table 1.1 Prevalence of AD Accross The Seven Major Markets
- (2006)
- Table 1.2. AD Revenue Forecast ($m) for Seven Major
- Markets,2007-2012,2017 & 2022
- Table 1.3 SWOT Analysis on Alzheimer's disease market
- Table 2.1 Prevalence of AD 2006-2050 In Three Geographical Regions
- Table 3.1 Assessment Scale for Defining Magnitude of AD
- Table 3.1 contn'd Assessment Scale for defining magnitude of AD
- Table 3.2 Summary of AD drugs clinical data
- Table 3.3 SSRIs Considered in Managing Depression in AD
- Table 3.4 Atypical antipsychotic agents considered in managing depression in AD
- Table 3.5 Typical antipsychotic agents considered in managing depression in AD
- Table 3.6 Anxiolytic Drugs Benzodiazepines Considered in Managing Depression in AD
- Table 3.7 Mood-Stabilizing (anti-agitation) Drugs Considered in Managing Depression in AD
- Table 5.1 The Global AD Market, 2004-2006
- Table 5.2 Sales for AD Therapies in the US, 2003-2006
- Table 5.3 US AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
- Table 5.4 J apan AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
- Table 5.5 Sales Revenues of AD Agents in France, 2003-2006
- Table 5.6 France AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
- Table 5.7 Sales Revenues for AD Therapies in Germany, 2003-2006
- Table 5.8 Germany AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
- Table 5.9 Sales Revenues for AD Therapies in the UK, 2003-2006
- Table 5.10 UK AD sales revenue forecast ($m), 2007-2012,2017 & 2022
- Table 5.11 Italy's Sales Revenues for AD Therapies, 2003-2006
- Table 5.12 Italy AD Sales Revenue Forecast ($m), 2007-2012,2017 & 2022
- Table 5.13 Spain Sales Revenues for AD Therapies, 2003-2006
- Table 5.14 Spain AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
- Table 6.1 Summary of Aricepts Approved indications for AD
- Table 6.2 Present Aricept Extra indications in Major Markets
- Table 6.3 Patent Expiration on leading AD products in Major Markets
- Table 7.1 Alzheimer's disease phase III Pipeline
- Table 7.2 Alzheimer's disease phase II Pipeline
- Table 7.3 Alzheimer's disease phase I Pipeline
- List of Charts
- Chart 1.1. Demographics of Alzheimer's Disease Across Major Markets, 2006
- Chart 1.2. Aricept Total Sales Revenue Across Seven Major Markets, 2006
- Chart 1.3. Memantine Total Sales Revenue Across Six Major Markets, 2006
- Chart 1.4. Razadyne (previously Reminyl) Total Sales Revenue Across Six Major Markets, 2006
- Chart 1.5. Exelon Total Sales Revenue Across Six Major Markets, 2006
- Chart 2.1. Current and Projected Global Prevalence of Alzheimer's Disease
- Chart 2.2 Global Cost of AD During 2003-2005 ($bn)
- Chart 5.1 The Global Sales ($m) of AD drugs, 2004-2006
- Chart 5.2 The Global Market Share for Leading AD Drugs, 2006
- Chart 5.3 Sales for AD Therapies in the US, 2003-2006
- Chart 5.4 Market Share for AD agents in the US, 2006
- Chart 5.5 US AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
- Chart 5.6 Aricept Sales Revenue,2003-2006
- Chart 5.7 Japan AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
- Chart 5.8 Sale Revenues of AD Agents in France, 2003-2006
- Chart 5.9 Market Share for AD Agents in France,2006
- Chart 5.10 France AD Sales revenue Forecast ($m), 2007-2012, 2017 & 2022
- Chart 5.11 Sales Revenues for AD Therapies in Germany, 2003-2006
- Chart 5.12 Market Share for AD Agents in Germany,2006
- Chart 5.13 Germany AD Sales Revenue Forecast ($m), 2007-2012,2017 & 2022
- Chart 5.14 Sales Revenues for AD Therapies in the UK, 2003-2006
- Chart 5.15 Market Share for AD Agents in the UK, 2006
- Chart 5.16 UK AD Sales Revenue Forecast ($m), 2007-2012,2017 & 2022
- Chart 5.17 Sales Revenues for AD Therapies in Italy, 2003-2006
- Chart 5.18 Market Share for AD Agents in Italy,2006
- Chart 5.19 Italy AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
- Chart 5.20 Market Share for AD Agents in Spain, 2006
- Chart 5.21 Market Share for AD Agents in Spain, 2006
- Chart 5.22 Spain AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
AbstractAlzheimers disease (AD) is the third leading cause of death in recent times and with an unprecedented patient potential, this disease area attracts awareness from a broad base of stake holders. With the grey population being the single most influencial factor in driving the economic growth within this sector, Visiongain believes the real market of the AD industry still remains untapped.
Over the past decade the AD market has been flagged by a quartet of approved pharmacological agents; acetyl cholinesterase inhibitors (AchEIs), N-methyl D-aspartate (NMDA) receptor antagonists and other non-AD specific therapeutics for management of comorbidities. The AchEIs comprise products from some of the leading larger pharmaceutical companies;
- Esia/Pfizer's Aricept (Donepizel)
- Novartis Exelon (Rivagstigmine) and
- Shire/J&J's Razadyne (galantamiune) previously Reminyl and recent entrant a non-AchEI
- NMDA receptor antagonist Mementine, marketed in the US by Forest as Nemanda and in EU as Ebixa by Lundbeck Mementine
However, all the listed drugs only elicited modest clinical benefits in treating the various stages of the AD. In addition, the UK National Institute of Clinical Excellence (NICE) decision not to place the drugs on the NHS for reimbursement generated major controversy across the larger markets, only to affect the potential revenue growth on the major drugs particularly in the UK, one of the significant markets.
What questions does the report answer?
- Which regions have the highest prevalence of AD diseases today and by 2050?
- Do you know the cost of AD across the larger markets?
- Who are the market leaders in this class of therapy?
- What market share was accounted for by the quartet of AD drugs in the major markets?
- Do you know the magnitude of the controversy generated by NICE's, as it deems the major drugs not cost-effective on the NHS?
- Do you know how much the AD market will be worth by Q4 of 2007 and its potential value by 2012, 2017 and 2022?
- Which first line drugs will be coming off patent by 2012 and what are the economic implications to the market?
- Do you know which drugs have been withdrawn from the neurodegenerative market?
- Which molecules are currently in the AD pipelines that are deemed to answer unmet therapeutic needs in the future?
Revenues of the only approved AD drugs across the major markets (US, Japan, France, Germany, Italy, Spain and the UK) totaled over $3 billion in 2006, with revenues expected to exceed $5 billion by 2012. By 2014, Visiongain anticipates that, all the AD approved therapies will come of patents in the major markets signaling a potential genericisation of the AD market.
With looming patient potential over the major products, Visiongain's market analysis forecast a-to- be lucrative era during the mid-term of our forecast where we believe, the sector will see the penetration of highly innovative AD products presently in late-phase clinical studies into the AD arena, only heralded by modest therapies, as opposed to the large outcry for highly effective drugs complimented by value for money by inter-country healthcare regulatory authorities.
With country-by-country focus on the markets of:
- US
- UK
- Germany
- Japan
- France
- Italy
- Spain
This report includes detailed five-year forecasts over the period 2007-2012, and NOW features 10 and 15 year forecasts to help you understand the medium-term prospects for these markets.
Why You Must Buy This Report:
This report features tables, graphs and charts, news, insights, the past and present developments in Market. This report will provide you with the complete understanding of the demand for a shift from modest therapies to highly efficacious drugs for the treatment of AD. Amongst the catalogue of products in the AD pipeline is the insurgence of the highly anticipated Anti Beta-Amyloid Therapies, a treatment against beta-amyloid plaque formation the hallmark of AD. This area of research including Biomarkers has generated a high level of interest from; top-tier companies, the major players in the AD circle and niche companies alike.
This visiongain report is the single tool to equip you with the latest trends in all regional markets and why all (stakeholders) demand a new generation of drugs to improve the quality of live suffers of AD and their caregivers. Visiongain recommends this astute report to the major players in the field as it will arm you with the clinical challenges that larger companies face to date, thus the rising inherent cost of R&D expenditure to in order meet the requirements set by major regulatory authorities for larger evidence of clinical data before any authorisation.
When you buy this report, you will also get an understanding, through our overview; of how present changes in Governmental Pharmaceutical Policies with respect to cost-cutting coupled with re/no imbursement has had consequential impact on the AD market products in the 7MM. The Alzheimer's Disease Market Analysis & Forecasts 2007-2022 report is a must buy, because it presents in-depth and unbiased financial analysis for the near-term, medium-term and the long-term, market dynamics. When you buy the Visiongain 2007 MS report, you will be buying current and vital information on the vast array of compounds in pipeline that are marked for potential success in the long-term treatment of AD.
Unique benefits to you when you order this report:
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Full searchable report when you buy the company or corporate editions
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
